ArticleJBMR plus2026
Osteocytes regulate osteoprotegerin expression via the p38-MAPK-CREB pathway in rheumatoid arthritis.
Article in JBMR plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is accompanied by systemic and local bone loss, yet the regulation of osteoclast-modulating factors within human osteocytes under inflammatory conditions remains incompletely understood. As an exploratory study, we analyzed surgically resected femoral heads from patients with RA and osteoarthritis (OA). Micro-CT of standardized cancellous regions showed no significant differences in trabecular microarchitectural parameters between groups. In contrast, immunoblot analysis of cortical bone from the femoral neck demonstrated higher osteoprotegerin (OPG) protein levels in RA than in OA. To investigate the underlying mechanism, we examined osteocytes under inflammatory stimulation using the mouse osteocyte-like cell line MLO-Y4 and osteocyte-enriched bone fractions (OEBFs). Among tested cytokines, TNF-α most strongly induced osteoclast-regulatory transcripts and increased OPG protein levels and secretion. TNF-α activated p38-MAPK and cyclic adenosine monophosphate (AMP) response element-binding protein (CREB) signaling, and pharmacologic inhibition of either p38-MAPK activity or CREB activity reduced TNF-α-induced OPG protein accumulation. Chromatin immunoprecipitation (ChIP) further showed enhanced recruitment of CREB to a responsive region within the OPG promoter after TNF-α stimulation. Finally, osteocyte-conditioned medium altered osteoclast morphology and reduced expression of an osteoclast lineage marker during RANKL-driven differentiation, while OPG neutralization did not produce a dominant reversal of these effects. Together, these findings indicate that OPG is upregulated in femoral neck cortical bone from patients with RA and that TNF-α can enhance osteocytic OPG expression via a p38-MAPK-CREB axis, alongside additional osteocyte-derived factors that modulate osteoclast maturation. This study provides evidence from human femoral head specimens of increased OPG in RA cortical bone and suggests that the p38-MAPK-CREB axis may represent an underappreciated regulatory component of osteocyte-derived OPG under inflammatory conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.